Second Generation CLL Treatment: Zanubrutinib + Sonrotoclax | Constantine Tam, MD, MBBS | ASH 2023 

Interview with Constantine Tam, MD, MBBS, from Alfred Health at ASH 2023. Filmed December 11, 2023.
ASH ABSTRACT: Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study
ash.confex.com/ash/2023/webpr...
The HealthTree Foundation brings information from the experts to the patients! Learn more at healthtree.org/
Donate to the HealthTree Foundation or learn more about additional blood cancer support we offer here: give.healthtree.org/campaign/...
HealthTree Cure Hub helps you find your best treatment options and accelerate cure for blood cancers. Join today at www.healthtree.org/